UK’s NICE Says Alzheimer’s Disease Drug Kisunla Is Not Cost-EffectiveBy Press Room2 November 2024 The United Kingdom medicines authority approved the Alzheimer’s disease drug Kisunla (donanemab) last week for certain patients. This follows the…